Ixabepilone to Treat Cervical Cancer

Inclusion Criteria

• •Patients must fulfill all of the following criteria to be eligible for study admission:
• •1. Age greater than or equal to 18 years.
• •2. Histologic or cytologic confirmation of cervical carcinoma, squamous or non-squamous. Within the non-squamous cohort is adenocarcinoma and adenosquamous as well as non-squamous (not otherwise specified).
• •3. Subjects with unresectable recurrent cervical cancer are eligible.
• •4. Measurable disease that can be assessed using RECIST (Response Evaluation Criteria in Solid Tumors) criteria.
• •5. Performance Status ECOG (Eastern Cooperative Oncology Group) 0-2.
• •6. Life expectancy of 3 months or greater.
• •7. Suitable candidate for receiving planned therapy as evidenced by screening laboratory assessments of hematologic, renal, hepatic, and metabolic functions: platelet count greater than or equal to 75,000/mm\^3, absolute granulocyte count (AGC) greater than or equal to 1,000/mm\^3, serum creatinine less than or equal to 1.6 or a measured creatinine clearance greater than or equal to 40 ml/min, SGPT (serum glutamic pyruvic transaminase) and SGOT (serum glutamic oxaloacetic transaminase) less than or equal to 2.5 times the NL (normal limit), and total bilirubin less than or equal to 1.5 times the NL (in patients with clinical evidence of Gilberts' disease, less than or equal to 3 times the NL).
• •Note: A diagnosis of Gilbert s disease will be made in the presence of (1) unconjugated hyperbilirubinemia noted on several occasions; (2) normal results from CBC (complete blood count) count, reticulocyte count, and blood smear; (3) normal liver function test results; and (4) an absence of other disease processes that can explain the unconjugated hyperbilirubinemia.
• •8. Greater than or equal to 4 weeks from prior radiation, intravenous chemotherapy or immunotherapy; greater than or equal to 6 weeks from prior nitrosourea; greater than or equal to 2 weeks from a prior phase 0 study .
• •9. No serious intercurrent medical illness.
• •10. The ability to understand and willingness to sign a written informed consent form, and to comply with the protocol.
• •11. Prior therapy with cisplatin or carboplatin is required.